TLDR: Absci, a clinical-stage biotech company, has announced a significant collaboration with Oracle Cloud Infrastructure (OCI) and AMD. This partnership aims to dramatically accelerate drug discovery processes, particularly for biologics, by leveraging Absci’s generative AI Drug Creation Platform with OCI’s advanced AI infrastructure and AMD’s next-generation hardware. The initiative seeks to streamline design cycles, enhance performance, and reduce costs in therapeutic development.
AUSTIN, Texas and VANCOUVER, Washington – September 11, 2025 – Absci, a pioneering clinical-stage biotech company at the forefront of generative AI-powered therapeutic development, today unveiled a strategic collaboration with Oracle Cloud Infrastructure (OCI) and AMD. This alliance is set to revolutionize drug discovery by significantly accelerating the development of biologics through Absci’s innovative generative AI Drug Creation Platform.
Absci’s platform will harness OCI’s robust AI infrastructure and AMD’s cutting-edge hardware, consolidating its computational resources to expedite biologics design cycles. The company has specifically chosen OCI as the foundational technical environment for developing its sophisticated AI models and scaling its extensive AI workflows. This strategic move has already enabled Absci to accelerate the development and operational aspects of its AI Drug Creation Platform, facilitating large-scale molecular-dynamics (MD) simulations and comprehensive end-to-end antibody design processes.
Building on this initial success with OCI, Absci is further strengthening its capabilities by partnering with AMD. This collaboration will integrate AMD’s next-generation Instinct™ MI355X GPUs into the platform, aiming to boost performance and scalability for its AI Drug Creation Platform.
Sean McClain, Founder and CEO of Absci, emphasized the significance of this partnership, stating, “Our mission is to push the boundaries of how we design new therapeutics. With OCI and AMD, we are pairing our cutting-edge AI models with best-in-class infrastructure. This collaboration accelerates our ability to bring novel therapeutics to patients while laying the technical foundation for the next generation of AI-powered drug-discovery workflows.”
Oracle’s contribution includes OCI’s bare metal instances, which are powered by 5th Generation AMD EPYC™ processors and feature ultrafast RDMA cluster networking. This configuration provides Absci with the critical low-latency networking and high throughput necessary for large-scale model training and high-resolution molecular-dynamics simulations, which are crucial for refining antibody-antigen interactions. Absci has reported that direct, bare-metal access to AMD GPUs within a single, flat-network supercluster has allowed them to eliminate hypervisor overhead, reduce inter-GPU latency to as little as 2.5 microseconds, and achieve terabytes-per-second throughput for checkpointing and data streaming.
Dan Spellman, Vice President, AI and OCI, Healthcare & Life Sciences at Oracle, commented on the collaboration: “Absci’s generative AI-driven drug discovery is the kind of breakthrough workflow OCI was built for. By combining bare metal GPUs, OCI Compute E6 instances, ultrafast RDMA networking, and high-performance storage, we’re providing the predictable performance and close engineering collaboration Absci needs to push the boundaries of biologics design.”
Ram Peddibhotla, Corporate Vice President, Data Center GPU Cloud Business at AMD, added, “By combining OCI with AMD EPYC CPUs, AMD Instinct GPUs and our open ROCm software platform, this collaboration provides the performance and scalability needed to advance complex biologics design and support more efficient discovery workflows.”
Also Read:
- Oracle Health Advances Healthcare AI with New Agentic Capabilities for Patient Engagement, Revenue Cycle, and Clinical Trials
- Briya Unveils AIRE: A Clinical-Grade AI Assistant Revolutionizing Medical Research and Drug Development
Absci, with facilities in Vancouver, Washington, New York City, and Switzerland, is dedicated to utilizing generative AI to design therapeutic antibodies and other biologics, integrating AI algorithms with synthetic biology validation processes to bring novel treatments to patients more rapidly.
